Literature DB >> 25015057

Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.

Emily S Van Laar, Jayashri Mehta Desai, Aminah Jatoi.   

Abstract

PURPOSE: Because as many as 30% of cancer patients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’ perceived knowledge gaps, barriers,and educational interests relevant to CINV.
METHODS: An Internet-based survey was developed and was electronically disseminated to members of Medscape, an international Internet-based continuing medical education provider.
RESULTS: A total of 2388 health care providers responded to the survey. Although breakthrough nausea and vomiting was the most common CINV-related issue they managed in the preceding year, managing delayed nausea was the most problematic in that time period. Thirty-two percent of health care providers delayed or discontinued a patient’s chemotherapy because of CINV. Cost of antiemetics, patients’ poor adherence to antiemetic regimens, and health care providers’ underestimation of risk for CINV were all barriers to effective management. Health care providers expressed a wide range of educational interests, including managing breakthrough CINV, keeping up with novel antiemetic agents, and learning about emerging approaches for CINV prevention/management.
CONCLUSIONS: This survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancer patients at risk for or suffering from CINV.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25015057      PMCID: PMC4291310          DOI: 10.1007/s00520-014-2325-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  9 in total

1.  Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.

Authors:  John M Salsman; Steven M Grunberg; Jennifer L Beaumont; Miriam Rogers; Diane Paul; Marla L Clayman; David Cella
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  A shortage of oncologists? The American Society of Clinical Oncology workforce study.

Authors:  Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2007-03-14       Impact factor: 44.544

3.  Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders.

Authors:  M M WINTROBE; C M HUGULEY
Journal:  Cancer       Date:  1948-09       Impact factor: 6.860

4.  Facilitators and barriers to survey participation by physicians: a call to action for researchers.

Authors:  Carrie N Klabunde; Gordon B Willis; Lawrence P Casalino
Journal:  Eval Health Prof       Date:  2013-09       Impact factor: 2.651

Review 5.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

6.  Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting.

Authors:  Steven Grunberg; Rebecca A Clark-Snow; Jim Koeller
Journal:  Support Care Cancer       Date:  2010-01-19       Impact factor: 3.603

Review 7.  Emerging treatments in chemotherapy-induced nausea and vomiting.

Authors:  Steven M Grunberg; Barbara Slusher; Hope S Rugo
Journal:  Clin Adv Hematol Oncol       Date:  2013-02

8.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Authors:  Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

9.  Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.

Authors:  Ralph Boccia; Steven Grunberg; Edwin Franco-Gonzales; Edward Rubenstein; Daniel Voisin
Journal:  Support Care Cancer       Date:  2013-01-26       Impact factor: 3.603

  9 in total
  25 in total

1.  Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.

Authors:  Sun Young Rha; Su Kyung Song; Chung Eun Lee; Yeonhee Park; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-06-08       Impact factor: 3.603

2.  Response.

Authors:  Emily S Van Laar; Jayashri Mehta Desai; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2015-05-15       Impact factor: 3.603

3.  Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need.

Authors:  Andrea Tendas; Pasquale Niscola; Alessio Perrotti; Teresa Dentamaro; Paolo de Fabritiis; William Arcese
Journal:  Support Care Cancer       Date:  2015-03-28       Impact factor: 3.603

4.  Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.

Authors:  Pascale Dielenseger; Sussanne Börjeson; Cheryl Vidall; Annie Young; Patrick Jahn
Journal:  Support Care Cancer       Date:  2019-02-19       Impact factor: 3.603

5.  A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers.

Authors:  Rui Chen; Hongyun Wang; Wen Zhong; Salvatore Chessari; Corinna Lanzarotti; Alberto Bernareggi; Pei Hu
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-02       Impact factor: 3.333

6.  GDF15 Induces Anorexia through Nausea and Emesis.

Authors:  Tito Borner; Evan D Shaulson; Misgana Y Ghidewon; Amanda B Barnett; Charles C Horn; Robert P Doyle; Harvey J Grill; Matthew R Hayes; Bart C De Jonghe
Journal:  Cell Metab       Date:  2020-01-09       Impact factor: 27.287

7.  A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Authors:  Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons
Journal:  Support Care Cancer       Date:  2017-03-09       Impact factor: 3.603

8.  Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).

Authors:  Bernardo Rapoport; Daniel Chua; Allen Poma; Sujata Arora; Yan Wang; Luis Enrique Fein
Journal:  Support Care Cancer       Date:  2015-05-05       Impact factor: 3.603

9.  Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.

Authors:  Lee Schwartzberg; Brooke Harrow; Lincy S Lal; Janna Radtchenko; Gary H Lyman
Journal:  Am Health Drug Benefits       Date:  2015 Jul-Aug

10.  Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China.

Authors:  Xianglong Zong; Jie Zhang; Xin Ji; Jie Gao; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.